In research, FACT is invaluable for evaluating the effectiveness of new cancer treatments and interventions. By including HRQoL as an endpoint in clinical trials, researchers can better understand the broader impact of treatments beyond traditional clinical outcomes. This is critical for assessing the risk-benefit ratio of new therapies and ensuring that they offer tangible improvements in patients' lives.
